Amsterdam: Hospital pharmacists have spent three winters rationing antibiotics, insulin and children’s painkillers. Lawmakers now want that scramble to end. The Critical Medicines Act, on which Parliament and Council negotiators struck a provisional deal in May, hands regulators fresh tools to keep essential drugs flowing when supply chains buckle.

The law targets a narrow but vital slice of the pharmacy shelf. It covers substances patients cannot easily do without, many of which Europe sources from a single overseas factory. When one plant stumbles, the shortage ripples across every member state at once.

To blunt that risk, the Act steers public money and procurement toward manufacturers that make critical products inside the Union. Governments can now reward diversified supply chains in their tenders instead of simply chasing the lowest bid, a habit that quietly hollowed out European production for decades.

The European Medicines Agency sits at the centre of the new machinery. Its shortages steering group gains a mandate to run vulnerability checks across the Union list of critical medicines and to feed those findings straight into policy. The agency welcomed the agreement and is expanding its shortages monitoring platform so companies and regulators can swap warning signals faster.

Negotiators also built in a role for joint purchasing. Smaller countries, which drug makers often serve last, can band together and buy medicines of common interest as a bloc, gaining leverage that only larger markets used to enjoy.

Industry groups broadly back the shift, though they warn that reshoring production will cost money and take years. Building a sterile injectables line is not a switch regulators can flip in a single budget cycle. Critics on the health committee counter that the Act leans too heavily on incentives and too lightly on binding stockpiling duties.

The Council has framed the measure as a lesson drawn straight from the pandemic, when borders closed and factories in Asia throttled exports. Officials insist the goal is resilience rather than autarky; Europe will still import, but it will no longer depend on one supplier for a drug that keeps diabetics alive.

Formal adoption should follow later this year, once lawyers finish the text and both institutions vote. Patients will not feel the change overnight. Yet if the next respiratory season arrives without the familiar empty shelves, the Act will have earned its place in the pharmacy.